As a result, most MI patients have low reflow, and ≈30% of MI patients have no reflow after revascularization therapy, which causes persistent hypoxia in local myocardial tissue, resulting in poor patient outcomes.[6] Numerous emerging therapeutic approaches have been developed to address this challenge, including stem cell therapy or cytokine therapy, such as vascular endothelial activity factor (VEGF) administration. The gene discussed is VEGFA; the disease is myocardial infarction.